Wealth Enhancement Advisory Services
RCUS icon

Wealth Enhancement Advisory Services’s Arcus Biosciences RCUS Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$218K Buy
9,161
+82
+0.9% +$2.31K ﹤0.01% 3670
2026
Q2 		$263K Buy
+9,079
New +$224K ﹤0.01% 3332

Other funds holding RCUS

Gilead Sciences
Gilead Sciences Foster City, California $1.46B AUM 71.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Wealth Enhancement Advisory Services's RCUS Position: Q3 2026 in Review

Wealth Enhancement Advisory Services increased its Arcus Biosciences (RCUS) stake by 0.9% in Q3 2026, buying an estimated $2.31K and bringing the position to 9,161 shares worth $218K. The position accounts for ﹤0.01% of the portfolio, ranked #3670.

Wealth Enhancement Advisory Services first reported a position in RCUS in Q2 2026 and has held it in 2 quarters since. The position peaked at $263K in Q2 2026. 111 funds tracked by Wall St. Rank hold RCUS as of Q3 2026.

  • Wealth Enhancement Advisory Services held 9,161 shares of Arcus Biosciences worth $218K as of Q3 2026.
  • Wealth Enhancement Advisory Services bought 82 Arcus Biosciences shares in Q3 2026, an estimated $2.31K.
  • Arcus Biosciences made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #3670 holding.
  • Wealth Enhancement Advisory Services first reported a position in Arcus Biosciences in Q2 2026 and has held it in 2 quarters since.
  • Wealth Enhancement Advisory Services's Arcus Biosciences position peaked at $263K in Q2 2026.
  • 111 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.